All
FDA Fast Tracks Investigational Drug for Potential Approval in Lung Cancer Subtype
October 4th 2022Treatment with an investigational drug elicited a median progression-free survival (time from treatment until disease progression or death) of 8.9 months among patients with a form of unresectable or metastatic squamous non-small cell lung cancer, according to trial findings.
A 3-time Neuroblastoma Survivor Reflects on How Childhood Cancer Has Changed Over the Past 10 Years
September 30th 2022Ten years after being diagnosed with cancer, 11-year-old, 3-time neuroblastoma survivor Micah Bernstein and her father, Jeff, discuss how childhood cancer has changed over the past decade.
Patients Can Help Move the Needle Forward in Bladder Cancer Clinical Trials With Participation
September 29th 2022As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about how patients can find clinical trials they may be eligible for.
Combining Old and New Therapies in Advanced Bladder Cancer Shows Promise for the Future
September 29th 2022As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about how currently available agents are being investigated in combination with one another.